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Abstract A growing number of published articles report
estimates from meta-analysis or meta-regression on health
state utility values (HSUVs), with a view to providing input
into decision-analytic models. Pooling HSUVs is prob-
lematic because of the fact that different valuation methods
and different preference-based measures (PBMs) can gen-
erate different values on exactly the same clinical health
state. Existing meta-analyses of HSUVs are characterised
by high levels of heterogeneity, and meta-regressions have
identified significant (and substantial) impacts arising from
the elicitation method used. The use of meta-regression
with few utility values and inclusion criteria that extend
beyond the required utility value has not helped. There is
the potential to explore greater use of mapping between
different PBMs and valuation methods prior to data syn-
thesis, which could support greater use of pooling values.
Researchers wishing to populate decision-analytic models
have a responsibility to incorporate all high-quality evi-
dence available. In relation to HSUVs, greater under-
standing of the differences between different methods and
greater consistency of methodology is required before this
can be achieved.
Key Points for Decision Makers
Searching and synthesis of health state utility values
(HSUVs) to populate decision models should
incorporate all good-quality evidence, but the
variability of utility scores by elicitation methods
generates a problem for pooling values through
meta-analysis.
Stricter inclusion criteria for meta-regression or
meta-analysis of HSUVs may help.
There is potential for greater use of mapping
algorithms between HSUVs prior to meta-analysis,
although careful consideration should be given to the
appropriateness of the mapping function and the
additional level of uncertainty associated with
mapped values.
1 Introduction
The evaluation of healthcare technologies is increasingly
reliant upon decision-analytic models. Where quality-ad-
justed life-years (QALYs) are used as the overall outcome
measure for a decision model, each health state included in
the model requires a health-related quality-of-life score or
health state utility value (HSUV). Good practice in
parameter estimation relies on the principles of evidence-
based medicine, hence, aims to include all (unbiased)
evidence and employ formal evidence synthesis tech-
niques, with systematic review and meta-analysis [1] being
the highest level of evidence. That said, the diversity of
& Tessa Peasgood
T.Peasgood@sheffield.ac.uk
1 School of Health and Related Research, University of
Sheffield, Regent Court, Regent Street, Sheffield S1 4DA,
UK
PharmacoEconomics (2015) 33:1101–1105
DOI 10.1007/s40273-015-0310-y
methods for generating QALYs [2] and the variability
across the values generated by these different methods
leads to a quandary over whether meta-analysis of utility
values will be appropriate.
We are interpreting utility here to mean a measure of
the social judgement of the value of a particular health
state. Health economists use a number of different
methods to extract that value, resulting in the same
health state being attributed different (sometimes really
quite different) utility scores. This variability arises from
four factors: (1) who is asked (and when) to value health
states (patients, ex-patients, or members of the public);
(2) the technique used to extract preferences and esti-
mate values [the most common being time trade-off,
standard gamble (SG), visual analogue scale (VAS) and
discrete choice experiment]; (3) different variants of
each of the general method (such as the exact question
wording, the mode of administration or the use of props);
and (4) different preference-based measures (PBMs) or
instruments with different descriptive systems, including
different items and response options, valued using dif-
ferent methods.
Meta-analysis provides a means to pool data collected
across a number of studies and produce a weighted average
of the measure of interest, thereby, generating a more
precise measure. Most HSUV studies report more than one
mean utility value (e.g. patients may complete more than
one PBM); consequently any meta-analysis of HSUVs
needs to adjust for the fact that these values will be cor-
related. Given the potential sources of variability of
HSUVs, it is unsurprising that conventional tests find that
pooled HSUVs reveal considerable heterogeneity (e.g. [3,
4]).
2 Existing Use of Meta-Analysis and Meta-
Regression for Utility Values
Meta-regressions [5] allow researchers to explore hetero-
geneity and the impact of different elicitation methods.
Existing meta-regressions (see Table 1) on HSUVs have
found substantial differences in values between elicitation
methods.
These differences are worryingly large. Indeed, Sturza
[6], reporting on her meta-regression for lung cancer,
argued that since methodological factors affect utility
values, lung cancer researchers ‘‘should avoid direct
comparisons on lung cancer utility values elicited with
dissimilar methods’’ (p. 691).
Some HSUV synthesis has avoided some of these
problems by only using meta-analysis on the EQ-5D
(Peasgood et al. [14] for osteoporosis states; Doth et al.
[15] for pain states) as this is the measure explicitly pre-
ferred by the National Institute for Health and Care
Excellence (NICE) [16]. Others have conducted a separate
meta-analysis for each overall method or instrument (Liem
et al. [17] for renal replacement therapy states; Post et al.
[18] for stroke; Mohiuddin and Payne [19] for depression).
Whilst a weighted average of EQ-5D values may be ade-
quate for NICE Health Technology Appraisal submissions,
for non-NICE submissions, we are left with a decision as to
which value to use to populate a decision model. This
choice is likely to impact substantially upon the mean
values used (e.g. Mohiuddin and Payne [19] reported a
pooled SG value for mild depression of 0.69 compared
with only 0.56 for the pooled EQ-5D estimate) and on the
final incremental cost-effectiveness ratios [20]. Further-
more, a meta-analysis on one particular instrument or
Table 1 Some example coefficients on utility instruments and elicitation methods in meta-regressions
References Health states Coefficient on utility instrument/elicitation method (all with p\ 0.05) Reference case
Sturza [6] Lung cancer Assessment of quality of life (AQoL) [7]: -0.263 SG
McLernon et al. [3] Chronic liver disease states TTO: 0.116; transformed VAS: 0.152 EQ-5D
Si et al. [4] Hip fracture SG: 0.36 EQ-5D
Vertebral fracture Health Utilities Index (HUI) [8]: 0.22 EQ-5D
Lung et al. [9] Diabetes TTO or SG: 0.068 EQ-5D
Wyld et al. [10] Chronic kidney disease Mapped EQ-5D: -0.14 TTO
Bremner et al. [11] Prostate cancer Quality of Well-being (QWB) [12]: -0.09 TTO
Djalalov et al. [13] Colorectal cancer SG: -0.13 TTO
SG standard gamble, TTO time trade-off, VAS visual analogue scale
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method results in considerable loss of evidence and infor-
mation, which goes against the researcher’s responsibility
to incorporate all high-quality evidence available.
3 Recommendations
How do we use the very best evidence under the circum-
stances of considerable parameter variation across
methodologies? The problem may not be as bad as it at first
seems. It may be that these elicitation method differences
identified in meta-regressions are inflated. Firstly, some
meta-regressions for HSUVs have been conducted on fairly
small numbers of utility values. Secondly, meta-regressions
have included values that do not appear to be measuring the
same thing, i.e. the utility score on a scale of 0 (dead) to 1
(full health) representing how the relevant society views
the value of a particular clinical health state.
Meta-regressions with only a few studies and consider-
able study heterogeneity run the risk of showing false
positives [21]; hence, a dummy variable for the elicitation
method may appear to be statistically significant when it is
not. Whilst there are no hard and fast rules for the appro-
priate sample size in meta-regression, a ratio of at least ten
studies to each covariate is often recommended [5]. For
meta-regressions of effectiveness, a minimum of four
studies in a categorical subgroup variable has been rec-
ommended [22], while more are required to conduct sig-
nificance testing. Meta-regressions of HSUVs have been
conducted with small numbers of utility values (e.g.
McLernon et al. [3] conducted a meta-regression with nine
covariates and 40 utility values), and some have very few
utility values in each category (e.g. Wyld et al. [10]
included a covariate for Short Form 6 dimension with only
one utility value identified that used this instrument).
The pooling of utility values should only be attempted
where the data are valuing the same clinical health state for
the appropriate population. The breadth of the health state
for which utility values are sought should be dictated by the
economic model, and utility values should confidently
reflect that exact health state required. Vignettes, which
verbally describe a particular (hypothetical) clinical health
state to allow individuals who are not in that particular
health state to estimate a utility score, may have a useful
role in populating economic models in the absence of any
other utility values. However, they introduce another layer
of uncertainty and may offer no additional benefit when
values on the actual desired health state are available. In
the meta-regression by Sturza [6], values derived from
asking members of the public to link lung cancer vignettes
to an EQ-5D state are included alongside direct patient EQ-
5D responses without recognition of the superiority of the
latter evidence. Making a judgement on whether a study is
identifying a utility for the appropriate health state requires
detailed information on the exact study population (in-
cluding study selection, drop out, missing values and
clinical diagnosis), and this is unfortunately not always
available [19]. When in doubt, preference should be for
including only studies where it is reasonable to assume that
the utility refers to the desired population.
The pooling of utility values should also only include
utilities anchored on the dead to full-health scale. This
would exclude values where the top anchor is symptom
free (which would exclude some values used in Bremner
et al. [11]) or ‘normal’ rather than full health (which would
exclude some values used in Peasgood et al. [23], Tengs
and Lin [24, 25] and Sturza [6]). Where there is uncertainty
on whether the values really are utility scores, such as
when the assessment method is not stated, these should not
be included (which would exclude some values used in
Tengs and Lin [25]).
It is possible that some PBMs may not adequately
identify important aspects of a particular clinical health
state. Where there is strong psychometric evidence that a
particular instrument lacks validity for the health condition
of interest (e.g. see Longworth et al. [26] for a review), a
synthesis that excludes those values will be useful for
sensitivity analysis.
Where an economic model is to be used to support
decision making in a particular country, the desired utility
values are those that give the social value of the health state
as judged by the relevant population from that country.
Utility scores using tariffs from other countries reflect
different sets of preferences, and unless it is believed that
preferences should be universal, or the value sets are very
similar, the rational for pooling utilities that use different
country-specific tariffs is not clear. Considerable inter-
country differences in the social tariff of the EQ-5D have
been identified, with differences varying across the EQ-5D
distribution [27]. Including a country-specific tariff
dummy, hence, shifting the intercept, will not capture this
variability across the distribution or differences in the
weight given to different items in the instrument. To
include utility data from other countries would require
patient level data to enable the appropriate social tariff to
be applied or a mapping from one country tariff to another
using more sophisticated methods (e.g. [28]).
Even where we have included only utility values on the
same clinical health state, the identified utility values are
still likely to show variability across instruments and
elicitation methods. For PBMs, it is likely that the different
descriptive systems drive the variation as much as differ-
ences in valuation method [29]. Including the instrument as
an intercept term on meta-regression is a limited approach
as it does not pick up the relative weights attributed to the
different domains within an instrument (including zero if
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the item is not included at all). An alternative approach
would be to use mapping between instruments, at the
aggregate or, if possible, the individual patient level.
Whilst mapped values may still differ in terms of both
mean and variance compared with direct values (e.g. Wyld
et al. [10] found EQ-5D values mapped from Short Form
12 and Short Form 36 to have different values to direct EQ-
5D values) and may not be feasible where descriptive
content does not substantially overlap, where mapping is
possible, the pooling of mapped-utility values could offer a
means of generating an estimate that incorporates more of
the relevant evidence and has a smaller variance. That said,
consideration should be given to the quality of the mapping
function, particularly at the ends of the distribution [30],
and the appropriateness of the population on which the
mapping function was based.
In addition to generating a pooled mean value, consid-
eration also needs to be given to an assessment of uncer-
tainty of the parameter. Ara and Wailoo [31] note that this
should incorporate the uncertainty from any mapping
functions used, the uncertainty from tariff scores and
uncertainty from the output of the descriptive system.
More generally, pooling HSUVs would be aided if there
was a greater consistency of valuation methods between
instruments. Where instruments adopt different descriptive
systems, effort could still be made to generate a social tariff
that adopts a standardised methodology. This would
facilitate greater understanding of the source of differences
between instruments.
The advantages of adopting a systematic review of
utility values to populate economic models are clear—the
adoption of a clear methodology to follow in terms of
searching (see [32]) and transparent reporting of findings.
This includes details of study characteristics that would
allow modellers to select the most appropriate value [33]
for both the main model and any sensitivity analysis. The
advantage of including a meta-analysis or meta-regression
is the use of all available good-quality evidence in gener-
ating the value to be used. Yet even with stricter inclusion
criteria (excluding values that are not the appropriate
utilities), we are still likely to be left with a considerable
degree of heterogeneity across utility values. Higgins [34]
has presented the case that in relation to study effect sizes
‘‘any amount of heterogeneity is acceptable, providing
both that the predefined eligibility criteria for the meta-
analysis are sound and that the data are correct.’’ (p. 1158).
Where we are aiming to measure the same thing—the
social value of a particular health state—we ought to be
able to combine values. More work is required on under-
standing sources of variation in utility values, particularly,
variation driven by differences in the descriptive system.
For England and Wales, the current NICE methods
guide states that when it is necessary to take HSUVs from
the literature ‘‘the methods of identification of the data
should be systematic and transparent. The justification for
choosing a particular data set should be clearly explained.
When more than one plausible set of EQ-5D data is
available, sensitivity analyses should be carried out to show
the impact of the alternative utility values’’ [16]. This does
not then imply a requirement for meta-analysis on EQ-5D
values at present. However, given the growing number of
publications that incorporate meta-analysis or meta-re-
gression of HSUVs, this guidance may change in the
future.
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